Effect of Myocardial Viability Assessed by Cardiac Magnetic Resonance on Survival in Patients With Severe Left

Jonathan Yap1, Fang Yi Lim1, Fei Gao1

  • 1Cardiology, National Heart Centre Singapore Singapore Singapore.

Circulation Reports
|March 11, 2021
PubMed

Insights

Assessing myocardial viability with cardiac magnetic resonance (CMR) late gadolinium enhancement (LGE) helps predict survival benefits from coronary artery bypass grafting (CABG) in ischemic heart failure patients. This finding requires validation in larger studies.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Medical Diagnostics

Background:

  • Myocardial viability assessment is crucial for revascularization decisions in ischemic heart failure.
  • The prognostic utility of cardiac magnetic resonance (CMR) late gadolinium enhancement (LGE) remains debated.
  • Left ventricular ejection fraction (LVEF) ≤35% defines the study cohort with ischemic heart failure.

Purpose of the Study:

  • To evaluate the prognostic value of CMR-LGE for predicting outcomes in ischemic heart failure patients undergoing revascularization.
  • To determine if LGE extent influences survival benefit from coronary artery bypass grafting (CABG) versus optimal medical therapy (OMT).

Main Methods:

  • Retrospective analysis of 165 ischemic heart failure patients (LVEF ≤35%) who underwent CMR before CABG or OMT.
  • Myocardial segments with LGE >50% wall thickness were classified as non-viable.
  • Outcomes assessed included all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events.

Main Results:

  • A higher number of non-viable myocardial segments correlated with increased all-cause and cardiovascular mortality in the CABG group (P<0.05).
  • This association was not significant in the optimal medical therapy (OMT) group (P>0.05).
  • Anterior wall viability did not impact patient outcomes.

Conclusions:

  • CMR-assessed myocardial viability may identify patients who benefit differentially from CABG.
  • These findings suggest LGE could guide revascularization strategies in ischemic heart failure.
  • Larger prospective studies are needed to validate these hypotheses.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
138
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
115
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
139